Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hanwha Files For Korea Approval For Biosimilar Of Amgen’s Enbrel

This article was originally published in PharmAsia News

Executive Summary

Although Hanwha may soon be allowed to sell the biosimilar in Korea, it remains to be seen how its partner Merck will proceed in ex-Korea markets given patent uncertainties.


Related Content

Is Merck Less Bullish on Biosimilars?
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
Korean Court Upholds Employee Non-competition Clause In LG Contract; Puts Brakes On Samsung's Manhunt For Biosimilar Specialists
Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts